Today on #WorldBrainTumorDay, we’re not just remembering, we're acting. Kiyatec's 3D Predict™ is the first revolutionary leap in glioma treatment in 2 decades. Join us in embracing this new dawn of personalized cancer therapy. #Kiyatec #3DPredict #PrecisionOncology

Knowledge is power, especially when it comes to cancer. 3D Predict™ bridges the gap between genetic insights and practical treatment decisions. Elevate your cancer treatment strategy by making it part of your process. See how: bit.ly/3DPredictHCP #Kiyatec #3DPredict

Before treating patients with HGG, consider a cutting-edge approach to cancer treatment planning: 3D Predict™ Glioma. If cancer cells die in our test, they're likely to die in the body. See how it works at: bit.ly/3DPPlatform #3DPredict #Kiyatec

A study of 3D Predict™ on a glioblastoma patient showcases its power in identifying effective therapies, marking a leap in precision medicine for brain tumors. More details: bit.ly/43rPgje #3DPredict #Kiyatec

We're at #AACR in San Diego! Come to booth #3020 to see how 3D Predict™ & KIYA-Predict™ are reshaping cancer care with personalized therapy. Join us in advancing oncology. #Kiyatec #3DPredict #KIYAPredict #AACR2024

Curious about Kiyatec's live tissue processing? CEO Eric Perreault unveils their 25,000-sq-ft lab's role in pioneering functional precision oncology. Dive into the full interview here: bit.ly/3wZbX22 #3DPredict #Kiyatec #FunctionalPrecisionMedicine

TMZ was developed decades ago, yet it's still the leading first-line chemo agent for the treatment of glioblastoma (GBM) patients despite its less than stellar outcomes. Isn't it time for a new standard? Test first with #3DPredict™, then treat. bit.ly/3SGc5L9

Don't forget to log in today at noon EST for an interactive webinar on using 3D Predict™ to direct therapy for patients with high-grade glioma. Live Q&A to follow! bit.ly/49Ayd0n #Kiyatec #3DPredict #PrecisionOncology #ClinicalCases #Webinar

Ninety-five percent of all investigational cancer drugs fail in clinical trials.  To help remedy this critical issue, the @NIH and @US_FDA established the Microphysiological Systems Program to accelerate the development of more predictive preclinical models. @keliomics ' breakthrough technology enables the stable, ex vivo culture of whole human tissues for at least 8 weeks. Our technology is ideal for pre-clinical efficacy testing and clinical trial planning planning by showing which therapies are most effective against the patients' tumors. Learn more at keliomics.com.  #tumormicroenvironment #TNBC #extracellualrmatrix #ExVivoTumors #breastcancer #CancerResearch #3DPredict #PrecisionMedicine #Chemotherapy #clinicaltrials

Big thanks to the @SeattleSciFdtn and all of those we met at the 9th Annual Innovative Approaches to Brain Tumor Management. If you missed us, see how 3D Predict™ works at: bit.ly/3DPredictHCP #Innovation #BrainTumor #Kiyatec #3DPredict

In Seattle for the @SeattleSciFdtn 9th Annual Innovative Approaches to Brain Tumor Management? Stop by and let's talk about 3D Predict™ as part of your treatment tailoring toolbox. Can't make it? Learn more about us at: bit.ly/3DPredictHCP #Kiyatec #BrainTumor #3DPredict

We're paving the way for functional precision oncology with our cutting-edge technologies. Now, our all-new website reflects it. Kiyatec.com #Kiyatec #3DPredict #KIYAPredict

In high-grade glioma (HGG), #Kiyatec 3D Predict™ accurately predicted therapeutic response rates in >85% cases. Talk to us about ordering it for your HGG patients: info@Kiyatec.com Source: Shuford S, et al. Neurooncol Adv. 2021;3(1). #3DPredict

Eric Perreault takes over from founder and previous CEO Matt Gevaert, who will continue to serve on our Board of Directors. With Eric at the helm, our mission to improve patient outcomes and revolutionize cancer care remains steadfast. #KIYAPredict #3DPredict #Kiyatec

Thanks to all of you who met us in Miami! If you missed learning about 3D Predict™ Glioma at the 6th Annual Miami Brain Symposium, shoot us an email and let's talk: info@Kiyatec.com #3DPredict #Glioma #BrainCancer #PrecisionMedicine #CancerTreatment

Existing therapies for GBM provide incremental benefits but ultimately fail and choice of therapies, particularly at recurrence, is frequently random. There's a better way to customize treatment to a specific tumor/patient: #3DPredict Glioma. Let's talk: info@Kiyatec.com

Delighted to see our portfolio’s @3DPredict aligners offered by our local Los Altos orthodontists. They took NYC by storm and now expanding to west coast

Exciting developments in glioma treatment! @MrugalaMaciej et al just published an abstract using #3DPredict to assess therapeutic efficacy in 12 patients with high-grade gliomas. Read it here: bit.ly/3DPredict If you're at SNO 2023, stop by booth #215/217 to learn more.

Diagnosing #Glioma involves a LOT of testing. Now, we have a test that can tell oncologists which chemotherapy will be most effective against a patient's specific tumor PRIOR to treatment. Let's talk about #3DPredict™: info@Kiyatec.com

Treatment for high-grade gliomas can be physically taxing for patients. Visit our booth at the Society for Neuro-Oncology's (SNO) Annual Meeting to see how #3DPredict™ Glioma can help you identify effective chemotherapies. Can't make it but still want to talk? info@Kiyatec.com